{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:12:41Z","timestamp":1790820761348,"version":"4.1.0"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Rifaximin showed moderately high MICs (the MIC at which 90% of the isolates tested were inhibited = 50 \u03bcg\/ml) for 145 bacterial enteropathogens from patients with traveler's diarrhea acquired in Mexico during the summers of 1997 and 1998. Rifaximin concentrations in stool the day after oral administration (800 mg daily for 3 days) were high (average, 7,961 \u03bcg\/g), proving the value of the drug.<\/jats:p>","DOI":"10.1128\/aac.44.8.2205-2206.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"2205-2206","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":153,"title":["In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration"],"prefix":"10.1128","volume":"44","author":[{"given":"Zhi-Dong","family":"Jiang","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Center for Infectious Disease, School of Public Health and Medical School, University of Texas\u2014Houston,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Ke","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->University of Texas M.D. Anderson Cancer Center,2 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Palazzini","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Alfa Wassermann, S.p.A. Bologna, Italy3; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Riopel","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Salix Pharmaceuticals Inc., Palo Alto, California4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Dupont","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Center for Infectious Disease, School of Public Health and Medical School, University of Texas\u2014Houston,1"},{"name":"<!--label omitted: 5-->St. Luke's Episcopal Hospital and Baylor College of Medicine,5 Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/030006058801600410","article-title":"Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin.","volume":"16","author":"Corazza G. R.","year":"1988","unstructured":"Corazza G. R. Ventrucci M. Strocchi A. Sorge M. Pranzo L. Pezzilli R. Gasbarrini G. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J. Int. Med. Res. 16 1988 312 316","journal-title":"J. Int. Med. Res."},{"key":"e_1_3_2_3_2","first-page":"51","article-title":"Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.","volume":"16","author":"Descombe J. J.","year":"1994","unstructured":"Descombe J. J. Dubourg D. Picard M. Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int. J. Clin. Pharmacol. Res. 16 1994 51 56","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJM198209303071401","article-title":"Treatment of travelers' diarrhea with trimethoprim\/sulfamethoxazole and with trimethoprim alone.","volume":"307","author":"DuPont H. L.","year":"1982","unstructured":"DuPont H. L. Reves R. R. Galindo E. Sullivan P. S. Wood L. V. Mendiola J. G. Treatment of travelers' diarrhea with trimethoprim\/sulfamethoxazole and with trimethoprim alone. N. Engl. J. Med. 307 1982 841 844","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1056\/NEJM199306243282507","article-title":"Prevention and treatment of traveler's diarrhea.","volume":"328","author":"DuPont H. L.","year":"1993","unstructured":"DuPont H. L. Ericsson C. D. Prevention and treatment of traveler's diarrhea. N. Engl. J. Med. 328 1993 1821 1827","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1159\/000007580","article-title":"Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.","volume":"59","author":"DuPont H. L.","year":"1998","unstructured":"DuPont H. L. Ericsson C. D. Mathewson J. J. Palazzini E. DuPont M. W. Jiang Z. D. Mosavi A. de la Cabada F. J. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 59 1998 708 714","journal-title":"Digestion"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.","volume":"49","author":"Gillis J.","year":"1995","unstructured":"Gillis J. Brogden R. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49 1995 467 484","journal-title":"Drugs"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1023\/A:1026648812439","article-title":"Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.","volume":"44","author":"Gionchetti P.","year":"1999","unstructured":"Gionchetti P. Rizzello F. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci. 44 1999 1220 1221","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0732-8893(93)90004-Q","article-title":"Antimicrobial activity and spectrum of rifaximin, a new tropical rifamycin derivative.","volume":"16","author":"Hoover W.","year":"1993","unstructured":"Hoover W. Gerlach E. Hoban D. Eliopoulos G. Pfaller M. Jones R. Antimicrobial activity and spectrum of rifaximin, a new tropical rifamycin derivative. Diagn. Microbiol. Infect. Dis. 16 1993 111 118","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1185\/03007999709113333","article-title":"Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double blind randomized trial.","volume":"13","author":"Miglio F.","year":"1997","unstructured":"Miglio F. Valpiani D. Ricca Rossellini S. Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double blind randomized trial. Curr. Med. Res. Opin. 13 1997 593 601","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_2_11_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\n          4th ed.\n          1997 Approved standard. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002280050426","article-title":"Rifaximin systemic absorption in patients with ulcerative colitis.","volume":"54","author":"Rizzello F.","year":"1998","unstructured":"Rizzello F. Gionchetti P. Venturi A. Ferretti M. Peruzzo S. Raspanti X. Picard M. Canova N. Palazzini E. Campieri M. Rifaximin systemic absorption in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 54 1998 91 93","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/infdis\/165.4.667","article-title":"High-level quinolone resistance in clinical isolates of Campylobacter jejuni.","volume":"165","author":"Segreti J.","year":"1992","unstructured":"Segreti J. Gootz T. D. Goodman L. J. Parkhurst G. W. Quinn J. P. Martin B. A. Trenholme G. M. High-level quinolone resistance in clinical isolates of Campylobacter jejuni. J. Infect. Dis. 165 1992 667 670","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","first-page":"131","article-title":"Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy.","volume":"45","author":"Verardi S.","year":"1990","unstructured":"Verardi S. Verardi V. Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy. Farmaco 45 1990 131 135","journal-title":"Farmaco"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.8.2205-2206.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.8.2205-2206.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:44:10Z","timestamp":1645461850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.8.2205-2206.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["10.1128\/AAC.44.8.2205-2206.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.8.2205-2206.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8]]},"assertion":[{"value":"2000-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-04-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}